

### UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	PPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/850,091	(	05/08/2001	Etsuko Matsunaga	206445US0CONT	1424
22850	7590	09/25/2002			
		ICCLELLAND M	EXAMINER		
	RSON DA	VIS HIGHWAY	IBRAHIM, MEDINA AHMED		
ARLINGIC	ON, VA 22202			ART UNIT	PAPER NUMBER
				1638	1
				DATE MAILED: 09/25/2002	$\mathfrak{H}$

Please find below and/or attached an Office communication concerning this application or proceeding.

<u>\</u>		Application No.	Applicant(s)					
		09/850,091	MATSUNAGA ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Medina Ibrahim	1638					
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHO THE N - Exter - If the - If NO - Failur - Any ro	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Issions of time may be available under the provisions of 37 CFR 1.11 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1)[	Responsive to communication(s) filed on 08 /	<u>May 2001</u> .						
2a)[	This action is <b>FINAL</b> . 2b)⊠ Th	is action is non-final.						
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)🖂	4)⊠ Claim(s) <u>1-26</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)⊠ Claim(s) <u>1-26</u> is/are rejected.								
7)	7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.								
Applicati	on Papers							
9)☐ The specification is objected to by the Examiner.								
10)⊠ The drawing(s) filed on <u>08 May 2001</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.								
· · · ·								
Priority under 35 U.S.C. §§ 119 and 120  13)   Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
	☐ All b)☐ Some * c)☐ None of:	i priority under 60 0.0.0. 3 110(6	(y (d) 51 (l).					
۵٫۱	1. ☐ Certified copies of the priority document	s have been received.						
	2. Certified copies of the priority documents have been received in Application No. <u>9/354,305</u> .							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)								
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)								
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)					
.S. Patent and Tr	rademark Office							

Page 2

Application/Control Number: 09/850, 091

Art Unit: 1638

## **DETAILED ACTION**

Claims 1-26 are pending and are under examination.

# Sequence Listing

No CRF and paper sequence listing have been filed with this application.

However, page 27, lines 15-16 of the specification recites sequences without sequence identifier. Applicant must submit a CRF and paper copy of the Sequence Listing as required in 37 CFR 1.821-1.825. Applicant must also amend the specification to include the SEQ ID NO for these sequences.

### Information Disclosure Statement

Initialed and dated copies of Applicant's IDS form 1449, Paper Nos. 2 and 4 are attached to the instant Office action.

#### **Drawings**

The drawings filed with this application have been approved.

### Priority

1. Acknowledgment is made of applicants' claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed in parent Application No. 09/354, 305, filed on 07/16/1999. It is noted, however, that the specific reference to the parent application as required by 35 U.S.C. 120 is missing. This should appear as the first sentence of the specification following the title, preferably as a separate paragraph. If

Application/Control Number: 09/850, 091

Art Unit: 1638

a parent application has become a patent, the expression "now Patent No. \_\_\_\_\_" should follow the filing date of the parent application.

# Double Patenting

The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Page 4

Application/Control Number: 09/850, 091

Art Unit: 1638

Claims 1-26 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 6, 294, 714 in view of Chua et al (US 6, 063, 985, filed January 1998). The claims in the instant application and the claims in the '714 patent are both drawn toward a method for introducing a vector comprising a desired gene, an adventitious shoot redifferentiation gene as a selectable marker gene under the control of a light inducible promoter, a removable DNA element derived from a site -specific recombination system, wherein the selectable marker gene is positioned to behave integrally with the removable DNA element, but not with the desired gene, transgenic plant or plant cell produced by such method. While the method claimed in the patent uses the adventitious shoot redifferentiation gene of ipt as a selectable marker gene and the instantly claimed method uses the adventitious shoot redifferentiation gene of CKI1, it would have been obvious to one of ordinary skill in the art to substitute an ipt gene with a CKI1 gene, given the teachings of Chua et al. Chua et al teach a plant transformation method that uses ipt and CKI1 genes as selectable markers and in the same manner (see at least column 2, line 25, column 3, line 26, and column 14). Therefore, the subject matter instantly claimed, a method for introducing a vector comprising an adventitious shoot redifferentiation gene, including a CKI1 gene, as a selectable marker, under the control of light-induced promoter, and a removable DNA element derived from site-specific recombination system, positioned to behave integrally with

Page 5

Application/Control Number: 09/850, 091

Art Unit: 1638

the CKI1 gene and not with the desired gene and transformed plants/plant cells produced by said method, would have been obvious over the method for introducing a vector comprising an adventitious shoot redifferentiation gene, including an ipt gene, as a selectable marker, under the control of light-induced promoter, and a removable DNA element derived from site-specific recombination system, positioned to behave integrally with the ipt gene and not with the desired gene and transformed plants/plant cells produced by said method, claimed in the patent '714.

# Claim Rejections - 35 USC § 102

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 1-4, 6-9 and 11-25 are rejected under 35 U.S.C. 102(b) as being anticipated by SUGITA et al (WO97/42334). Applicants note that the Abstract and figures are relied upon, since the publication is not in english language.

Sugita et al teach a method for transferring a desired gene into a plant comprising introducing a vector comprising the desired gene, an ipt gene as a selectable marker operably linked to a ribulose 2-phosphate carboxylase small subunit, a removable DNA factor located in a position so that it acts together with the selectable but not with the desired, wherein the selectable marker gene is optionally removable.

Application/Control Number: 09/850, 091

Art Unit: 1638

(see Abstract; Figures 2-15). Plants and plant cells transformed with said vector have also been disclosed by the reference. Therefore, all claim limitations are anticipated.

#### Remarks

No claim is allowed.

Papers relating to this application may be submitted to Technology Sector 1 by facsimile transmission. Papers should be faxed to Crystal Mall 1, Art Unit 1638, using fax number (703) 308-4242. All Technology Sector 1 fax machines are available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina a. Ibrahim whose telephone number is (703) 306-5822. The Examiner can normally be reached Monday -Tuesday from 8:00AM to 4:00PM and Wednesday-Thursday from 9:00AM to 3:00 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218.

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is (703) 308-0196.

September 22, 2002 mai

ELIZABETH F. McELWAIN
PRIMARY EXAMINER
GROUP 1800